ARD-101

DRUG5 trials

Sponsors

Aardvark Therapeutics, Inc.

Conditions

Bariatric SurgeryHyperphagiaHyperphagia in Prader-Willi SyndromeObesityPrader-Willi SyndromeWeight Gain

Phase 2

Study to Evaluate ARD-101 in Adults With Obesity

CompletedNCT05121441

Aardvark Therapeutics, Inc.Obesity

Start: 2021-11-15End: 2022-11-09Updated: 2025-01-22

A Study of Oral ARD-101 in Patients With Prader-Willi Syndrome

CompletedNCT05153434

Aardvark Therapeutics, Inc.Prader-Willi Syndrome

Start: 2022-05-27End: 2024-09-24Updated: 2026-09-08

Study to Evaluate ARD-101 in Adults Receiving Bariatric Surgery

CompletedNCT05215847

Aardvark Therapeutics, Inc.Bariatric Surgery, Obesity, Weight Gain

Start: 2022-03-01End: 2023-02-03Updated: 2025-02-11

Phase 3

ARD-101 for Treatment of PWS: The Hunger Elimination or Reduction Objective Trial

TerminatedNCT06828861

Aardvark Therapeutics, Inc.Hyperphagia, Prader-Willi Syndrome

Start: 2024-12-20End: 2026-05-07Updated: 2026-06-30

The Hunger Elimination or Reduction Objective (HERO ) Open -Label Extension (OLE) Trial

TerminatedNCT07197034

Aardvark Therapeutics, Inc.Hyperphagia, Hyperphagia in Prader-Willi Syndrome, Prader-Willi Syndrome

Start: 2024-07-23End: 2026-04-15Updated: 2026-06-30